Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28521243 | 0.90 | HRH3 (0.43) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL30129139 | 0.90 | HRH3 (0.43) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL31075110 | 0.85 | HRH3 (0.48) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL31576115 | 0.85 | HRH3 (0.48) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL24709631 | 0.84 | HRH3 (0.47) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL23705621 | 0.84 | HRH3 (0.47) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL23692945 | 0.83 | HRH3 (0.38) | HRH3ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL7749087 | 0.83 | SMN1; SMN2 (0.55) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL7879735 | 0.83 | HRH3 (0.51) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR | |
| SCHEMBL2433535 | 0.81 | ALDH1A1 (0.49) | HRH3ALDH1A1SMN1; SMN2MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3002285-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9862721-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| CN-101613321-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC | 2009-12-30 | — | — | CN | disclosed |
| CN-101597262-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-100525763-C | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2009-08-12 | — | — | CN | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| CN-1633290-A | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2005-06-29 | — | — | CN | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | HRH3 978/4885ALDH1A1 3202/4885SMN1; SMN2 3312/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | HRH3 3051/4885ALDH1A1 2600/4885SMN1; SMN2 49/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | HRH3 1008/4885ALDH1A1 3093/4885SMN1; SMN2 3253/4885 |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | HRH3 2397/4885ALDH1A1 1022/4885SMN1; SMN2 1848/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | HRH3 1008/4885ALDH1A1 3093/4885SMN1; SMN2 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.